Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. MU
5. META
6. FDX
7. IBM
8. PRIM
9. ACN
10. USO

Go back to Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

Brookline Capital Markets Reiterates Buy Rating on Intellia Therapeutics (NTLA)

June 26, 2024 5:27 AM EDT

Brookline Capital Markets analyst Leah RUsh Cann reiterated a Buy rating and $24.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst comments "Redosing is not planned for the NTLA-2001 for the ATTR amyloidosis program, and only resulted in three patients in the phase I study, due to their having been dosed at a suboptimal level in the dose... More